EU MDR CE Marking: Conformity Assessment Routes, EU DoC and EUDAMED Duties

1. Key takeaways

The European Union does not issue any CE registration certificate. The full chain that leads to the CE marking consists of three steps: complete the conformity assessment by selecting the Annex IX, Annex X or Annex XI route in accordance with Article 52, then issue the EU Declaration of Conformity under Article 19 and Annex IV, and finally affix the CE marking in accordance with Article 20 and Annex V. Which conformity assessment route applies is decided by the risk class of the device and by its device form, not by commercial preference or by the availability of a given notified body.

This sequence matters because each step feeds the next one. The conformity assessment route determines what evidence the EU Declaration of Conformity must reference, and the Declaration in turn determines whether the CE marking may be affixed at all and whether a notified body number must accompany it. Manufacturers that treat these three steps as independent paperwork tasks typically discover late that their route choice, their declaration content and their certificate scope do not align, forcing rework at the most expensive stage of the project. Planning the chain as one integrated sequence, starting from a documented classification decision, is the practical estimate of what a compliant pathway looks like under Regulation (EU) 2017/745.

2. Legal basis

All three entries concern the same regulation, so the dates are identical across the table: Regulation (EU) 2017/745 was adopted on 2017-04-05 and became applicable on 2021-05-26. The three Annexes IX, X and XI are alternative conformity assessment routes under Article 52, while Annex IV and Annex V govern the declaration and the marking that conclude the process. Annex VII Section 4.3 governs how the application to the notified body and the written agreement between the two parties must be documented, which has direct transitional consequences discussed below.

3. Expert insights

Insight one: the route is determined by the classification outcome, and a wrong classification makes the whole route wrong.

Under Article 52, devices map to different combinations of conformity assessment procedures according to their class: Class I devices that are non-sterile, non-measuring and not reusable surgical instruments are generally covered by a self-issued EU Declaration of Conformity without any notified body involvement, while Class IIa, Class IIb and Class III devices all require a notified body, with the depth of that involvement increasing with each class. Classification is therefore the entrance to the route selection exercise, not a parallel administrative matter. A classification error propagates through everything downstream: the notified body engagement, the technical documentation depth, the declaration content and even the transitional deadlines that may apply to legacy devices. Getting the class right first, and documenting the reasoning, is the single cheapest risk-control action in the whole project.

Insight two: the three Annexes solve three different problems and are not equivalent alternatives.

Annex IX is built around a quality management system audit combined with a technical documentation assessment and is the main route for most Class IIa and higher devices. Annex X (type-examination) addresses whether a representative sample meets the requirements, and is used in combination with Annex XI for some Class IIb and Class III devices. Annex XI (verification of product conformity) contains both a production quality assurance part and a product verification part, and often serves as a supplementary module to Annex IX. The three can be combined and are not mutually exclusive, which is a point manufacturers frequently misunderstand when they describe the framework as a simple three-way choice.

Insight three: the application step has explicit formal legal requirements.

Under Annex VII Section 4.3, the application for conformity assessment that the manufacturer submits to the notified body, together with the written agreement signed by both parties, constitutes the direct evidence of eligibility for the transitional extensions under Article 120(3c)(e). The dates on these two documents matter concretely: an application submitted on 2024-05-26 and an agreement signed on 2024-09-26 determine whether a legacy device qualifies for the extended deadlines of 2027-12-31 or 2028-12-31. Manufacturers should therefore treat these documents as compliance records with evidentiary weight, not as commercial correspondence, and should retain dated copies in the technical file.

Insight four: two continuing obligations remain after the CE marking is complete.

Affixing the CE marking does not end the obligations. Under Articles 29 and 31, manufacturers must complete the device registrations in EUDAMED, and under Article 83 they must operate a post-market surveillance system. From 2026-05-28, the relevant EUDAMED modules become mandatory in accordance with Commission Decision (EU) 2025/2371, so the registration actions cannot be deferred until after market entry. Planning the registration and surveillance setup as mandatory closure items of the CE marking project prevents the common situation in which devices are placed on the market with incomplete EUDAMED records and the manufacturer must remediate under time pressure.

4. Practical recommendations

1. At project initiation, produce the classification conclusion first and derive the route backwards from it; do not select a notified body before the class is fixed, and avoid the reverse order of finding an institution first and deciding the classification later.
2. In the written agreement signed with the notified body, state the scope, the milestones and the list of documents to be submitted, so that the agreement serves as the reference in any later dispute over what was assessed and when.
3. Prepare the EU Declaration of Conformity item by item in accordance with Annex IV, and keep the declaration content consistent with the certificate scope at all times.
4. Affix the CE marking to the specifications of Annex V, and verify whether a notified body number must accompany it for the device class concerned.
5. Set EUDAMED registration and the launch of the post-market surveillance system as mandatory items after CE, and include both in the project closure checklist.

5. Verification checklist

• □ A written classification conclusion has been obtained and the route has been selected on that basis
• □ The application for conformity assessment has been submitted to the notified body (Annex VII Section 4.3)
• □ A written agreement has been signed with the notified body and its date recorded
• □ The EU Declaration of Conformity has been prepared in accordance with Annex IV
• □ The CE marking has been affixed in accordance with Annex V and the notified body number checked
• □ The EUDAMED device registration status has been confirmed (mandatory modules from 2026-05-28)

GRZAN supports manufacturers, authorised representatives and importers across the EU MDR market with CE marking pathway selection and classification strategy. Our team helps you fix the risk class under Annex VIII, choose between the Annex IX, Annex X and Annex XI conformity assessment routes, prepare applications and written agreements under Annex VII Section 4.3, and coordinate the EU Declaration of Conformity, CE marking, EUDAMED registration and post-market surveillance setup as one integrated sequence. For a practical estimate of timelines, notified body scoping and documentation effort for your portfolio, contact GRZAN at info@grzanglobal.com.

Regulatory information verified as of 2026-10-29.